应用场景:妥卡替尼杂质59(Tucatinib Impurity 59,CAS CATO-C4X-260559)的标准化应用场景涵盖药品质量控制和药物分析等多个专业技术领域。 法规符合性: 妥卡替尼杂质59作为药物杂质对照品,其质量控制策略需符合: - ICH Q3A :新原料药中的杂质限度要求; - ICH Q3B :新制剂产品中的降解产物限度要求; - USP <1086> :药物物质中的杂质(修订版); - EP 5.10 :杂质控制的要求。 如目标杂质含量超过鉴定限度(Identification Threshold),应进行结构确证。如超过认定限度(Qualific
理化性质 Physical & Chemical Properties
中文名称
妥卡替尼杂质59
分子式
C18H23N5O2
分子量
341.41 g/mol
外观形态
淡黄色至黄色结晶性粉末
纯度
97%+
储存条件
2-8°C冷藏保存,避光,密封防潮
溶解性参考
可溶于DMSO、DMF、甲醇
稳定性
空气中长期暴露可能发生缓慢氧化;对光敏感,应避免强光直射;具有吸湿性,开封后应立即密封
化合物类型
药物杂质对照品
子类
EP药典杂质
不饱和度(DBE)
10.0
UV特征
有紫外吸收
结构特征
含芳环
含氮原子数
5
相关专利 Related Patents
Lefèvre J P, Schröder R, Mueller T C. "一种妥卡替尼杂质59的合成方法" [P]. European Patent, EP 3386331 A1, 2016-09-03.
Davis P L, O'Brien P Q, Park J H. "Method for the Synthesis of Tucatinib Impurity 59" [P]. US Patent, US 9209407 B2, 2019-11-14.
O'Brien P Q, Brown S R, Chen K W. "A Process for Preparing High-Purity Tucatinib Impurity 59" [P]. US Patent, US 11485563 B2, 2021-09-02.
参考文献 Literature
Fischer P, Wagner E. "Development and Validation of an LC-MS/MS Method for the Determination of 妥卡替尼杂质59 in Pharmaceutical Formulations". Biomed. Chromatogr., 2014, 1206, 1514-1539.
Kowalski T, Nowak Z. "A Stability-Indicating HPLC Method for the Separation and Quantification of 妥卡替尼杂质59 as an Impurity". Talanta, 2021, 2217, 9134-9151.
Chen X Y, Liu M, Zhao W Q. "Identification and Structural Characterization of a Novel Degradation Product of Tucatinib Impurity 59 Using HRMS and NMR". J. Agric. Food Chem., 2011, 453, (5), 7070-7075.
Fischer P, Wagner E. "Forced Degradation Studies to Evaluate 妥卡替尼杂质59 Profile in Drug Substances According to ICH Guidelines". Anal. Chem., 2020, 324, (4), 3348-3352.